Skip to main content
Erschienen in: BMC Nephrology 1/2022

Open Access 01.12.2022 | Case report

First case of a renal cyst infection caused by Desulfovibrio: a case report and literature review

verfasst von: Yoshiki Okamoto, Yoei Miyabe, Momoko Seki, Yusuke Ushio, Keisuke Sato, Eri Kasama, Kenichi Akiyama, Kazunori Karasawa, Keiko Uchida, Ken Kikuchi, Kosaku Nitta, Takahito Moriyama, Junichi Hoshino

Erschienen in: BMC Nephrology | Ausgabe 1/2022

Abstract

Background

Genus Desulfovibrio species is a sulphate-reducing anaerobic gram-negative rod that resides in the human oral cavity and intestinal tract. It was reported as the causative pathogen of bacteraemia and abdominal infections, but not renal cyst infection, and Desulfovibrio fairfieldensis has higher pathogenicity than other Desulfovibrio species.

Case presentation

A 63-year-old man was on haemodialysis for end-stage renal failure due to autosomal dominant polycystic kidney disease. On admission, he had a persistent high-grade fever, right lumbar back pain, and elevated C-reactive protein levels. His blood and urine cultures were negative. He received ciprofloxacin and meropenem; however, there was no clinical improvement. Contrast-enhanced computed tomography and plain magnetic resonance imaging revealed a haemorrhagic cyst at the upper pole of the right kidney. The lesion was drained. Although the drainage fluid culture was negative, D. fairfieldensis was detected in a renal cyst using a polymerase chain reaction. After the renal cyst drainage, he was treated with oral metronidazole and improved without any relapse.

Conclusions

To the best of our knowledge, this is the first reported case of a renal cyst infection with Desulfovibrio species. D. fairfieldensis is difficult to detect, and polymerase chain reaction tests can detect this bacterium and ensure better management for a successful recovery.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ADPKD
Autosomal dominant polycystic kidney disease
CRP
C-reactive protein
CT
Computed tomography
MRI
Magnetic resonance imaging
PCR
Polymerase chain reaction
18FDG PET/CT
18-fluorodeoxyglucose positron emission tomography/computed tomography
MALDI-TOF MS
Matrix-assisted laser desorption ionization time-of-flight mass spectrometry

Background

Genus Desulfovibrio is an anaerobic gram-negative rod and a type of sulphate-reducing bacteria belonging to more than 30 species residing in the human oral cavity, intestinal tract, and nature, including soil, sewage, and brackish water [1]. Desulfovibrio fairfieldensis has higher pathogenicity and more antimicrobial resistance than other Desulfovibrio species [14]. It may be the causative pathogen of bacteraemia and abdominal infections, such as abscesses and cholecystitis [1]. There are several reports of infections such as brain abscesses, meningitis, intra-abdominal abscesses, and bacteraemia caused by Desulfovibrio species [13, 57], but not renal cyst infection. Here, we report a case of renal cyst infection caused by D. fairfieldensis; this is the first such report.

Case presentation

A 63-year-old man, who was a glass craftsman and a sewer cleaner, on haemodialysis for 19 years due to autosomal dominant polycystic kidney disease (ADPKD), was referred by his family doctor for suspicion of renal cyst infection after presenting with a persistent fever of approximately 38 °C, right lumbar back pain, and elevated C-reactive protein (CRP) levels for the past 14 days. Although he had received intravenous ceftriaxone for two days and meropenem and levofloxacin for 12 days, he displayed no clinical improvement. On admission, he had a fever of 38.4 °C and negative blood and urine cultures (Fig. 1a). His blood tests revealed leucocytosis (9280/μL), thrombocytopenia (77000/μL), elevated CRP levels (11.09 mg/dL), and elevated procalcitonin levels (0.94 ng/mL). Plain computed tomography (CT) revealed a right renal cyst infection. Although treatment with intravenous ciprofloxacin (0.4 g/day) had been started, his clinical findings did not improve. Therefore, his treatment was changed to meropenem (0.5 g/day) on Day 9 to cover extended-spectrum β-lactamase-producing bacteria since meropenem had been reported to provide poor penetration into infected cysts but clinical improvement [8]. Contrast-enhanced CT and plain magnetic resonance imaging (MRI) were also performed (Fig. 1b). They revealed a haemorrhagic cyst at the upper pole of the right kidney, which was suspected to be the cause of the infection; percutaneous drainage of the renal cyst was performed on Day 13, and 200 mL of fluid was drained. The subsequent drainage volume was approximately 20 mL daily for 1 week. After drainage, the patient’s body temperature reduced to approximately 36.7 °C. In addition, the leucocytosis, thrombocytopenia, elevated CRP, and procalcitonin levels were resolved. The drainage fluid culture was negative for bacteria, including anaerobes and fungi. Therefore, a polymerase chain reaction (PCR) test of 16S rDNA using 27FN (AGAGTTTGATCMTGGCTCAG) and 1525R (AAAGGAGGTGATCCAGCC) primers was performed for purified DNA from the drainage fluid. On Day 30, it turned out that the obtained sequences were 99.7% identical (1500/1505 bp) to that of D. fairfieldensis ATCC 700045T(U42221). Therefore, on Day 31, his treatment was changed to oral metronidazole (1 g/day). The volume of drained fluid decreased to 0–2 mL on Day 34, and contrast-enhanced CT performed on Day 35 showed shrinkage of the renal cysts. His clinical findings normalised, and the drainage tube was removed on Day 36. The Japanese guidelines for treating renal cyst infection in patients with ADPKD recommend a treatment period of at least 4 weeks with antimicrobial agents [9]. Therefore, on Day 38, he was discharged and asked to continue oral metronidazole for 4 weeks. After that, there was no relapse of the infection.

Discussion and conclusions

Genus Desulfovibrio was first described in 1895 [10], and a human infection (bacteraemia associated with cholecystitis) with D. desulfuricans was first reported in 1987 [11]. However, it was later considered to be D. fairfieldensis in 2005 because the strain was positive for catalase and nitrate. Optical and electron micrographs of D. fairfieldensis were published in 1996 and 1997 [6, 12], and the first human infection with D. fairfieldensis was reported in Fairfield, Australia; it presented as a liver abscess [6]. Subsequently, we searched PubMed and Google scholar and 71 reported human cases of infection with Desulfovibrio species, including D. desulfuricans, D. fairfieldensis, D. piger, and D. legalli, were found in 26 articles (Table 1). D. fairfieldensis has been isolated from several sites of infection, including blood [24, 7, 12], peritoneal fluid [4], periodontal pockets [29, 30], the pelvis and colon [4], liver abscesses [6], and urine [5]. This report describes the first case of renal cyst infection caused by the genus Desulfovibrio. When our case is added to those previously reported, D. fairfieldensis infection is the most common (26 cases, 36%), followed by D. desulfuricans (24 cases, 33%), with bacteraemia and intra-abdominal infection being the commonest presentations (Table 2).
Table 1
Characteristics of 72 cases infected with Desulfovibrio species in 27 articles
Case no.
Age (yrs)
Sex
Infection
Source
Genus/species
Co-isolated/co-infected organism(s)
Identification
Time for positive incubation
Antibiotic susceptibility (Susceptible)
Antibiotic therapy
Outcome
Ref.
1
39
M
Sinusitis, gingivitis, brain abscess
Pus
D. desulfuricans
Streptococcus constellatus, Capnocytophaga ochracea, Cubacterium exiguum
Biochemical
10 days
AMC, IPM, MNZ
CTX, FOF, ONZ, PIP, PEF
Survived
[3, 13]
2
3
F
Appendix abscess
Pus
D. desulfuricans
B. merdae, E. lentum, E. coli, Enterococcus sp.
16S rDNA
unknown
unknown
unknown
Survived
[3]
3
61
F
Abdominal wall abscess, peritonitis
Pus
D. desulfuricans
B. fragilis, E. lentum, Clostridium sp., E. coli, Enterobacter cloacae, Enterococcus sp.
16S rDNA
unknown
unknown
unknown
Survived
Blood
D. desulfuricans
E. coli, Enterobacter cloacae
16S rDNA
unknown
unknown
4
80
M
Peritonitis
Peritoneal fluid
D. desulfuricans
unknown
16S rDNA
unknown
unknown
unknown
unknown
[14]
5
64
M
Bacteraemia
Blood
D. desulfuricans
None
16S rDNA
6 days
LVX, MXF, GAT, MNZ, CLI, IPM, ETP, DOX
DOX
Survived
[1]
6–8
unknown
unknown
unknown
unknown
D. desulfuricans
unknown
unknown
unknown
unknown
unknown
unknown
[4]
9
86
F
Bacteraemia, sacral decubitus ulcer
Blood
D. desulfuricans
E. lenta
16S rDNA
5 days
AMX, AMC, CLI, IPM, MNZ
CXM, AMX
Survived
[15]
10
60
M
Bacteraemia
Blood
D. desulfuricans
None
16S rDNA
8 days
unknown
CRO, ERY, PIP
Survived
[16]
11
69
F
Bacteraemia, ulcerative colitis
Blood
D. desulfuricans
Cytomegalovirus
16S rDNA
7 days
CLI, MNZ, ERY, AMC, MEM
PIP, CLI
Survived
[17]
12
87
M
Bacteraemia, colitis
Blood
D. desulfuricans
None
16S rDNA
12 days
SAM, TZP, AMC, FEP, MEM
SAM, CFZ, CAZ, CZO
Survived
[18]
13
69
M
Bacteraemia
Blood
D. desulfuricans
None
16S rDNA
5 days
IPM, MNZ
OFX, TZP
Survived
[19]
14
66
F
Hydronephrosis, suspected colon-ureteral/vesical fistula
Urine from percutaneous nephrostomy
D. desulfuricans
Anaerobic Gram-positive bacilli, anaerobic Gram-positive cocci, Streptococcus agalactiae, Actinobaculum schaalii, Propionimicrobium spp.
16S rDNA
unknown
CLI, MNZ, PEN
unknown
Died, secondary to herpes encephalitis
[20]
15
76
M
Bacteraemia, diverticulitis
Blood
D. desulfuricans
None
16S rDNA
3 days
MNZ
unknown
Survived
16
60
M
Colonic rupture
Spine tissue
D. desulfuricans
Mobiluncus curtisii, Candida albicans, Clostridium clostridioforme
16S rDNA
unknown
CLI, MNZ, PEN
unknown
Died
17
74
F
Bacteraemia, small-bowel obstruction
Blood
D. desulfuricans
None
16S rDNA
3 days
CLI, MNZ, TZP, ETP
unknown
Survived
18
57
M
Perforated acute appendicitis
Blood
D. desulfuricans
In peritoneal fluid: E. coli, K. pneumoniae, anaerobic Gram-negative and -positive rods
16S rDNA
4 days
CLI, MNZ, SAM, ETP
unknown
Survived
19
82
M
Bacteraemia, liver abscess
Blood
D. desulfuricans
None
Biochemical, 16S rDNA
15 days
AMP, AMC, IPM, PAPM, CLI, LVX
CMZ, TZP, AMC
Survived
[21]
20
73
F
Sepsis, liver abscess
Blood, pus
D. desulfuricans
E. coli
16S rDNA
3 days
LVX, MEM, SAM
MEM, SBT/CPZ, SAM, SBTPC
Survived
[22]
21
88
M
Bacteraemia, mediastinal abscess
Blood
D. desulfuricans
None
16S rDNA
3 days
unknown
TZP, CLDM, MNZ
Survived
[10]
22
53
M
Bacteraemia
Blood
D. desulfuricans
None
MALDI-TOF MS
3 days
MNZ, AMC, IPM, CLI
AMC, TZP
Survived
[23]
23
53
F
Trochanteric arthritis
Synovial fluid
D. desulfuricans
None
MALDI-TOF MS
6 days
MNZ, AMC
FEP, VAN, CRO, MNZ
Survived
[24]
24
67
M
Cholecystitis
Blood
D. fairfieldensis(*)
None
Biochemical
unknown
PEN, CLI, CHL, TET, ERY
None
Survived
[11]
25
82
M
Liver abscess
Pus
D. fairfieldensis
Fusobacterium varium
16S rDNA
7 days
MNZ
CTX, MNZ, AMP, CIP
Survived
[6]
26
75
M
Bleeding colonic polyps
Blood
D. fairfieldensis
None
16S rDNA
6 days
MNZ, CHL, CIP, IPM, AMC, TIM, AZM, CLI
LEX, CIP
Survived
[12]
27
46
F
Meningoencephalitis
Urine
D. fairfieldensis
None
16S rDNA
14 days
IPM, CIP, RIF, CLI, MNZ, CHL
AMP, RIF, EMB, INH, ACV, anti-mycobacterial drugs
Died
[5]
28
23
M
Perforating appendicitis, peritonitis
Blood
D. fairfieldensis
None
Biochemical, 16S rDNA
5 days
MNZ, IPM, CLI
FAM, MNZ
Survived
[3]
29
59
F
Intra-abdominal abscess
Pus
D. fairfieldensis
B. vulgatus, E. lentum, E. coli, K. pneumoniae, Streptococcus intermedius
16S rDNA
unknown
MNZ, CLI
unknown
Survived
30
85
M
Abdominal abscess
Blood
D. fairfieldensis
B. fragilis, B. uniformis, B. vulgatus, B. thetaiotaomicron, Clostridium innocuum, Clostridium sp., Enterococcus avium
16S rDNA
unknown
MNZ, CLI
unknown
Survived
31
65
M
Abdominal wall abscess
Pus
D. fairfieldensis
B. thetaiotaomicron, E. lentum, E. coli, K. pneumoniae, Proteus vulgaris, Enterococcus sp., Streptococcus intermedius
16S rDNA
unknown
MNZ, CLI
unknown
Survived
32
32
M
Appendicitis, peritonitis
Peritoneal fluid
D. fairfieldensis
unknown
16S rDNA
unknown
unknown
unknown
unknown
33
29
F
Appendicitis, peritonitis
Peritoneal fluid
D. fairfieldensis
unknown
16S rDNA
unknown
unknown
unknown
unknown
34
53
F
Peritonitis
Peritoneal fluid
D. fairfieldensis
unknown
16S rDNA
unknown
unknown
unknown
unknown
35
21
M
Appendicitis
Intra-abdominal collection
D. fairfieldensis
unknown
16S rDNA
unknown
unknown
unknown
unknown
36–45
unknown
unknown
unknown
unknown
D. fairfieldensis
unknown
unknown
unknown
unknown
unknown
unknown
[4]
46
77
M
Aftercholangiopancreatography
Blood
D. fairfieldensis
None
16S rDNA
4 days
MNZ, CIP
TIM, CIP
Survived
[2]
47
69
F
Bacteraemia
Blood
D. fairfieldensis
E. coli, Morganella morganii
16S rDNA
9 days
MNZ, CLI, IPM, BIPM, DOR
BIPM, CFZ
Survived
[7]
48
83
M
Bacteraemia, epidural abscess
Blood
D. fairfieldensis
Parvimonas micra
MALDI-TOF MS, 16S rDNA
7 days
None
None
Survived
[25]
49
63
M
Renal cyst infection
Pus
D. fairfieldensis
None
16S rDNA
None
None
MEM, MNZ
Survived
This
50
64
M
Peritonitis
Peritoneal fluid
D. piger
unknown
16S rDNA
unknown
unknown
unknown
unknown
[14]
51
83
F
Peritonitis
Peritoneal fluid
D. piger
unknown
16S rDNA
unknown
unknown
unknown
unknown
52
81
F
Rectal cancer
Peritoneal fluid
D. piger
unknown
16S rDNA
unknown
unknown
unknown
unknown
53
88
F
Peritonitis
Peritoneal fluid
D. piger
unknown
16S rDNA
unknown
unknown
unknown
unknown
54
14
M
Appendicitis
Abdominal collection
D. piger
unknown
16S rDNA
unknown
unknown
unknown
unknown
55
18
M
Peritonitis
Peritoneal fluid
D. piger
unknown
16S rDNA
unknown
unknown
unknown
unknown
56
9
M
Appendicitis, peritonitis
Peritoneal fluid
D. piger
unknown
16S rDNA
unknown
unknown
unknown
unknown
57–58
unknown
unknown
unknown
unknown
D. piger
unknown
unknown
unknown
unknown
unknown
unknown
[4]
59
73
F
Bacteraemia, abdominal abscess
Blood
D. piger
E. lenta, B. ovatus
16S rDNA
2 days
CLI, MNZ
unknown
Survived
[20]
60
63
M
Perforated acute appendicitis
Peritoneal fluid
D. piger
E. coli, Enterococcus sp., anaerobic Gram-negative rod
16S rDNA
unknown
unknown
unknown
Survived
61
unknown
unknown
Abdominal abscess
Peritoneal fluid
D. vulgaris
None
unknown
unknown
unknown
unknown
unknown
[26]
62–64
unknown
unknown
unknown
unknown
D. vulgaris
unknown
unknown
unknown
unknown
unknown
unknown
[4]
65
15
M
Brain abscess
Pus
D. vulgaris
Gram-positive cocci
Biochemical
2 days
KAN
AMC, CRO, AMK, LZD
Survived
[27]
66
70
F
Left-shoulder prosthetic-joint infection
Synovial fluid, prosthetic joint
D. legallii
None
16S rDNA
10 days
CLI, MNZ, ETP, AMC, CRO
unknown
Survived
[20]
67
unknown
unknown
Acute appendicitis
Peritoneal fluid
Desulfovibrio sp.
unknown
Biochemical
unknown
unknown
unknown
unknown
[28]
68
unknown
unknown
Perforating appendicitis
Peritoneal fluid
Desulfovibrio sp.
unknown
Biochemical
unknown
unknown
unknown
unknown
69
60
M
Perforated acute appendicitis
Blood
Desulfovibrio sp.
E. lenta, anaerobic Gram-negative rod, B. fragilis
16S rDNA
3 days
CLI, MNZ
unknown
Survived
[20]
70
74
M
Septic shock, intra-abdominal infection
Blood
Desulfovibrio sp.
Candida parapsilosis
16S rDNA
5 days
unknown
unknown
Died
71
45
M
Subphrenic abscess, abdominal infection
Blood
Desulfovibrio sp.
In subphrenic abscess: vancomycin-resistant enterococci
16S rDNA
5 days
unknown
unknown
Survived
72
93
F
Sigmoid diverticulitis
Blood
Desulfovibrio sp.
None
16S rDNA
6 days
CLI, MNZ
unknown
Died
(*) Although a human infection of Desulfovibrio species (specifically D. desulfuricans, presented as bacteraemia associated with cholecystitis) was first reported in 1987, the strain was considered as D. fairfieldensis in 2005
Ref Reference, M male, F female, MALDI-TOF MS Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, B Bacteroides, D Desulfovibrio, E. coli Escherichia coli, E. lenta Eggerthella lenta, E. lentum Eubacterium lentum, K Klebsiella, ACV acyclovir, AMC amoxicillin-clavulanic acid, AMK amikacin, AMP ampicillin, AMX amoxicillin, AZM azithromycin, BIPM biapenem, CAZ ceftazidime, CFZ cefazolin, CHL chloramphenicol, CIP ciprofloxacin, CLI clindamycin, CMZ cefmetazole, CRO ceftriaxone, CTX cefpodoxime, CXM cefuroxime, CZO cefozopran, DOR doripenem, DOX doxycycline, EMB ethambutol, ERY erythromycin, ETP ertapenem, FAM cefamandole, FEP cefepime, FOF fosfomycin, GAT gatifloxacin, INH isoniazid, IPM imipenem, KAN kanamycin, LVX levofloxacin, LZD linezolid, MEM meropenem, MNZ metronidazole, MXF moxifloxacin, OFX ofloxacin, ONZ ornidazole, PAPM panipenem, PEF pefloxacin, PEN penicillin, PIP piperacillin, RIF rifampin, SAM ampicillin-sulbactam, SBT/CPZ Cefoperazone sodium and sulbactam sodium, SBTPC sultamicillin, TET tetracycline, TIM ticarcillin-clavulanic acid, TZP piperacillin-tazobactam, VAN vancomycin
Table 2
Summary of clinical characteristics of cases of infection with Desulfovibrio species in 27 articles
Characteristics of cases
Total number of cases
72
Median age (years)
65
Female, male (%)
19, 32 (37, 63)
Infection (%)
 Abscess
15 (28)
  Abdominal abscess
8 (15)
  Liver abscess
2 (3.6)
 Bacteraemia
14 (26)
 Appendicitis
11 (20)
 Central nervous system infection
4 (7.4)
Source (%)
 Blood
26 (47)
 Peritoneal fluid
14 (26)
 Pus
9 (16)
 Urine
2 (3.6)
Total genus/species (%)
73
D. fairfieldensis
26 (36)
D. desulfuricans
24 (33)
D. piger
11 (15)
D. vulgaris
5 (6.8)
D. legallii
1 (1.4)
Co-isolate (%)
22 (54)
E. coli
9 (22)
E. lenta (E. lentum)
7 (17)
K. pneumoniae
3 (7.4)
 None
19 (46)
Identification (%)
 16S rDNA
47 (87)
 MALDI-TOF MS
3 (5.6)
 Biochemical
7 (13)
Time for positive incubation (%)
 2 days
2 (6.9)
 3 days
6 (21)
  > 3 days
21 (72)
  > 7 days
7 (24)
 Median (days)
5
Outcome (%)
 Survived
34 (89)
 Died
4 (11)
Percentages for each category are calculated excluding “unknown”. D Desulfovibrio, E. coli Escherichia coli, E. lenta Eggerthella lenta, E. lentum Eubacterium lentum, K Klebsiella, MALDI-TOF MS Matrix-assisted laser desorption ionization time-of-flight mass spectrometry
Because renal cyst infections in patients with ADPKD are frequent and refractory and patients on haemodialysis are immunocompromised [31], identification and eradication of the causative organism are essential [32]. The causative organisms of renal cyst infections have only been identified in 49% of cases, and the most common causative organisms are gram-negative rods from the intestinal tract [32, 33]. Therefore, the actual infection rate by Desulfovibrio species may be underestimated because of the difficulty in identifying anaerobic bacteria [3, 17] and the actual number of infections by anaerobic bacteria, including Desulfovibrio species, maybe much higher. No strain was cultured in this patient’s blood, urine, or renal cyst fluid, but D. fairfieldensis was detected in the renal cyst fluid by PCR testing. PCR is useful in identifying organisms that cannot be grown in vitro or in cases where existing culture techniques are not sensitive enough and/or require long incubation times due to its tremendous sensitivity, specificity, and amplification speed [34]. In previous reports, PCR tests using 16S rDNA were used to identify 87% of Desulfovibrio species, while biochemical methods were used in 13% (Table 2). Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) was also used in only 5.6% of the cases (Table 2); however, its use for organism identification is expected to increase because it is a novel method that can rapidly identify bacteria and be as accurate as 16S rDNA. In addition, 72% of the cases were identified after 3 days in cultures, and 24% were identified after 7 days (Table 2). Therefore, if the causative bacteria are unknown, performing the culture for a longer period is necessary.
In this case, contrast-enhanced CT and plain MRI identified the infected renal cyst, but 18-fluorodeoxyglucose positron emission tomography/CT (18FDG PET/CT) has been reported to be useful in the diagnosis of renal cyst infection [35, 36]. However, this method is not commonly used in Japan due to cost, where the national health insurance system allows the use of 18FDG PET/CT for malignant tumours mainly.
The routes of renal cyst infection include hematogenous routes and retrograde infection from the urinary tract. In the literature review, bloodstream infection was the most common among Desulfovibrio infection, followed by intra-abdominal infection, while urinary tract infection was less common at 3.6% (Table 2). He was in regular contact with soil and sewage, which are dwelling sites of the bacteria, due to his occupation. Since most of the Desulfovibrio species are also found in the environment, and since haemodialysis patients have reduced urine volume and are unable to cleanse themselves through urination, we suspected that the bacteria had entered the urinary tract and caused the infection retrogradely. However, it has been reported that D. fairfieldensis survives only in the human intestinal tract [4, 25], and we thought that it was more likely that the infection was haematogenous.
Infected cysts need early percutaneous cyst drainage, which provides the best treatment results because antibiotics alone do not usually treat the infection [33, 37]. In this case, the patient’s condition improved after drainage was performed.
For antimicrobial treatment of renal cyst infections, lipid-permeable antimicrobials with high penetration are recommended as first-line agents [32, 37]. Therefore, we also used ciprofloxacin as a quinolone, but with poor improvement. Then, we used meropenem which has been reported to have clinical improvement for cyst infection despite the poor penetration [8], but there was no improvement. The other antimicrobial agents for this patient were used as empirical treatments.
Optimal antimicrobial therapy for D. fairfieldensis remains controversial. One study showed that metronidazole had the highest antibacterial activity, while imipenem was effective against it [1]. Another study showed that imipenem, ciprofloxacin, clindamycin, chloramphenicol, and beta-lactams, except carbapenems, were ineffective [2]. Lipid-permeable antimicrobials such as metronidazole and clindamycin increase the concentrations of the antimicrobials in the renal cyst fluid [38]. Therefore, oral metronidazole was used for this patient. In addition, D. fairfieldensis may be more resistant to antimicrobial agents and have higher pathogenicity than other Desulfovibrio species [13]. Metronidazole was effective with good blood levels in the renal cysts of patients with ADPKD, including those on haemodialysis [38]. Summarising the previous reports of Desulfovibrio species infection, metronidazole showed the highest susceptibility (78%), and clindamycin was also effective (Table 3). However, metronidazole was used in only 23% of the patients; given that D. fairfieldensis is more resistant to antimicrobial agents and more pathogenic than other Desulfovibrio species [14], identifying the Desulfovibrio species, especially in D. fairfieldensis, by PCR tests, and using metronidazole, are essential for patient prognosis. In addition, because 54% of the patients with Desulfovibrio infection were complicated with other bacteria, there is concern that Desulfovibrio species can manifest when antimicrobial agents which are susceptible to other bacteria but resistant to Desulfovibrio are used (Table 2). The prognosis of Desulfovibrio infection was 11% of death, and treatment should be carefully selected, including appropriate drainage and antimicrobial agents.
Table 3
Summary of antimicrobial susceptibility of Desulfovibrio species and actual antibiotic therapy
 
Antimicrobial susceptibility (%)
Antimicrobial therapy (%)
MNZ
25 (78)
5 (23)
CLI
21 (66)
1 (4.5)
IPM
10 (31)
1 (4.5)
AMC
9 (28)
3 (14)
ETP
4 (13)
0
PEN
3 (9.4)
0
SAM
3 (9.4)
2 (9.1)
MEM
3 (9.4)
2 (9.1)
LVX
3 (9.4)
0
CIP
3 (9.4)
3 (14)
TZP
2 (6.3)
4 (18)
PAPM
1 (3.1)
0
AMP
1 (3.1)
2 (9.1)
CRO
1 (3.1)
3 (14)
AMC amoxicillin-clavulanic acid, AMP ampicillin, CIP ciprofloxacin, CLI clindamycin, CRO ceftriaxone, ETP ertapenem, IPM imipenem, LVX levofloxacin, MEM meropenem, MNZ metronidazole, PAPM panipenem, PEN penicillin, SAM ampicillin-sulbactam, TZP piperacillin-tazobactam
The essential recommendations for the general treatment of renal cyst infection, including Desulfovibrio species, are as follows: if the bacteria of renal cyst infection are unknown, focus on long-term culture studies, consider identification of the organism by 16S rDNA or MALDI-TOF MS, consider the possibility of multiple bacterial complications. Some bacteria have a high mortality rate, and drainage should be performed first if possible and appropriate antimicrobials should be administered according to the organism.
To conclude, this is the first report of a renal cyst infection with the genus Desulfovibrio species to the best of our knowledge. D. fairfieldensis has higher pathogenicity and more antimicrobial resistance than other Desulfovibrio species and is difficult to detect. PCR tests can detect this bacterium and ensure better management for a successful recovery.

Acknowledgements

We are deeply grateful to the nursing and medical team of the Department of Nephrology, Tokyo Women’s Medical University Hospital.
We thank Editage (www.​editage.​jp) for English language editing.

Declarations

Informed consent was obtained from the patient for the publication of this case report and accompanying images.
The patient in this case report provided written informed consent for his information and images to be published.

Competing interests

The authors declare no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Goldstein EJC, Citron DM, Peraino VA, Cross SA. Desulfovibrio desulfuricans bacteremia and review of human Desulfovibrio infections. J Clin Microbiol. 2003;41:2752–4. CrossRef Goldstein EJC, Citron DM, Peraino VA, Cross SA. Desulfovibrio desulfuricans bacteremia and review of human Desulfovibrio infections. J Clin Microbiol. 2003;41:2752–4. CrossRef
2.
Zurück zum Zitat Pimentel JD, Chan RC. Desulfovibrio fairfieldensis bacteremia associated with choledocholithiasis and endoscopic retrograde cholangiopancreatography. J Clin Microbiol. 2007;45:2747–50.CrossRef Pimentel JD, Chan RC. Desulfovibrio fairfieldensis bacteremia associated with choledocholithiasis and endoscopic retrograde cholangiopancreatography. J Clin Microbiol. 2007;45:2747–50.CrossRef
3.
Zurück zum Zitat Loubinoux J, Mory F, Pereira IAC, Faou AEL. Bacteremia caused by a strain of Desulfovibrio related to the provisionally named Desulfovibrio fairfieldensis. J Clin Microbiol. 2000;38:931–4.CrossRef Loubinoux J, Mory F, Pereira IAC, Faou AEL. Bacteremia caused by a strain of Desulfovibrio related to the provisionally named Desulfovibrio fairfieldensis. J Clin Microbiol. 2000;38:931–4.CrossRef
4.
Zurück zum Zitat Warren YA, Citron DM, Merriam CV, Goldstein EJC. Biochemical differentiation and comparison of Desulfovibrio species and other phenotypically similar genera. J Clin Microbiol. 2005;43:4041–5.CrossRef Warren YA, Citron DM, Merriam CV, Goldstein EJC. Biochemical differentiation and comparison of Desulfovibrio species and other phenotypically similar genera. J Clin Microbiol. 2005;43:4041–5.CrossRef
5.
Zurück zum Zitat Scola BL, Raoult D. Third human isolate of a Desulfovibrio sp. identical to the provisionally named Desulfovibrio fairfieldensis. J Clin Microbiol. 1999;37:3076–7.CrossRef Scola BL, Raoult D. Third human isolate of a Desulfovibrio sp. identical to the provisionally named Desulfovibrio fairfieldensis. J Clin Microbiol. 1999;37:3076–7.CrossRef
6.
Zurück zum Zitat Tee W, Dyall-Smith M, Woods W, Eisen D. Probable new species of Desulfovibrio isolated from a pyogenic liver abscess. J Clin Microbiol. 1996;34:1760–4.CrossRef Tee W, Dyall-Smith M, Woods W, Eisen D. Probable new species of Desulfovibrio isolated from a pyogenic liver abscess. J Clin Microbiol. 1996;34:1760–4.CrossRef
7.
Zurück zum Zitat Urata T, Kikuchi M, Hino T, Yoda Y, Tamai K, Kodaira Y, et al. Bacteremia caused by Desulfovibrio fairfieldensis. J Infect Chemother. 2008;14:368–70.CrossRef Urata T, Kikuchi M, Hino T, Yoda Y, Tamai K, Kodaira Y, et al. Bacteremia caused by Desulfovibrio fairfieldensis. J Infect Chemother. 2008;14:368–70.CrossRef
8.
Zurück zum Zitat Hamanoue S, Suwabe T, Ubara Y, Kikuchi K, Hazue R, Mise K, et al. Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts. BMC Nephrol. 2018;19:272.CrossRef Hamanoue S, Suwabe T, Ubara Y, Kikuchi K, Hazue R, Mise K, et al. Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts. BMC Nephrol. 2018;19:272.CrossRef
9.
Zurück zum Zitat Horie S. New strategy for the treatment of autosomal dominant polycystic kidney disease. Nihon Jinzo Gakkai Shi. 2015;57:254–61.PubMed Horie S. New strategy for the treatment of autosomal dominant polycystic kidney disease. Nihon Jinzo Gakkai Shi. 2015;57:254–61.PubMed
10.
Zurück zum Zitat Hagiya H, Kimura K, Nishi I, Yamamoto N, Yoshida H, Akeda Y, et al. Desulfovibrio desulfuricans bacteremia: a case report and literature review. Anaerobe. 2018;49:112–5.CrossRef Hagiya H, Kimura K, Nishi I, Yamamoto N, Yoshida H, Akeda Y, et al. Desulfovibrio desulfuricans bacteremia: a case report and literature review. Anaerobe. 2018;49:112–5.CrossRef
11.
Zurück zum Zitat Porschen RK, Chan P. Anaerobic vibrio-like organisms cultured from blood: Desulfovibrio desulfuricans and Succinivibrio species. J Clin Microbiol. 1977;5:444–7.CrossRef Porschen RK, Chan P. Anaerobic vibrio-like organisms cultured from blood: Desulfovibrio desulfuricans and Succinivibrio species. J Clin Microbiol. 1977;5:444–7.CrossRef
12.
Zurück zum Zitat McDougall R, Robson J, Paterson D, Tee W. Bacteremia caused by a recently described novel Desulfovibrio species. J Clin Microbiol. 1997;35:1805–8.CrossRef McDougall R, Robson J, Paterson D, Tee W. Bacteremia caused by a recently described novel Desulfovibrio species. J Clin Microbiol. 1997;35:1805–8.CrossRef
13.
Zurück zum Zitat Lozniewski A, Maurer P, Schuhmacher H, Carlier JP, Mory F. First isolation of Desulfovibrio species as part of a polymicrobial infection from a brain abscess. Eur J Clin Microbiol Infect Dis. 1999;18:602–3.CrossRef Lozniewski A, Maurer P, Schuhmacher H, Carlier JP, Mory F. First isolation of Desulfovibrio species as part of a polymicrobial infection from a brain abscess. Eur J Clin Microbiol Infect Dis. 1999;18:602–3.CrossRef
14.
Zurück zum Zitat Loubinoux J, Jaulhac B, Piemont Y, Monteil H, Faou AEL. Isolation of sulfate-reducing bacteria from human thoracoabdominal pus. J Clin Microbiol. 2003;41:1304–6.CrossRef Loubinoux J, Jaulhac B, Piemont Y, Monteil H, Faou AEL. Isolation of sulfate-reducing bacteria from human thoracoabdominal pus. J Clin Microbiol. 2003;41:1304–6.CrossRef
15.
Zurück zum Zitat Liderot K, Larsson M, Boräng S, Özenci V. Polymicrobial bloodstream infection with Eggerthella lenta and Desulfovibrio desulfuricans. J Clin Microbiol. 2010;48:3810–2.CrossRef Liderot K, Larsson M, Boräng S, Özenci V. Polymicrobial bloodstream infection with Eggerthella lenta and Desulfovibrio desulfuricans. J Clin Microbiol. 2010;48:3810–2.CrossRef
16.
Zurück zum Zitat Tanamachi C, Hashimoto K, Itoyama T, Horita R, Yano T, Tou K, et al. A case of Desulfovibrio desulfuricans cultured from blood in Japan. Rinsho Byori Jpn J Clin Pathology. 2011;59:466–9. Tanamachi C, Hashimoto K, Itoyama T, Horita R, Yano T, Tou K, et al. A case of Desulfovibrio desulfuricans cultured from blood in Japan. Rinsho Byori Jpn J Clin Pathology. 2011;59:466–9.
17.
Zurück zum Zitat Verstreken I, Laleman W, Wauters G, Verhaegen J. Desulfovibrio desulfuricans bacteremia in an immunocompromised host with a liver graft and ulcerative colitis. J Clin Microbiol. 2012;50:199–201.CrossRef Verstreken I, Laleman W, Wauters G, Verhaegen J. Desulfovibrio desulfuricans bacteremia in an immunocompromised host with a liver graft and ulcerative colitis. J Clin Microbiol. 2012;50:199–201.CrossRef
18.
Zurück zum Zitat Hagiwara S, Yoshida A, Omata Y, Tsukada Y, Takahashi H, Kamewada H, et al. Desulfovibrio desulfuricans bacteremia in a patient hospitalized with acute cerebral infarction: case report and review. J Infect Chemother. 2014;20:274–7.CrossRef Hagiwara S, Yoshida A, Omata Y, Tsukada Y, Takahashi H, Kamewada H, et al. Desulfovibrio desulfuricans bacteremia in a patient hospitalized with acute cerebral infarction: case report and review. J Infect Chemother. 2014;20:274–7.CrossRef
19.
Zurück zum Zitat Otto M-P, Berend M, Thibault F, Wey P-F, Gérôme P. Bactériémie à Desulfovibrio desulfuricans. Méd Et Maladies Infect. 2014;44:233–5.CrossRef Otto M-P, Berend M, Thibault F, Wey P-F, Gérôme P. Bactériémie à Desulfovibrio desulfuricans. Méd Et Maladies Infect. 2014;44:233–5.CrossRef
20.
Zurück zum Zitat Vasoo S, Mason EL, Gustafson DR, Cunningham SA, Cole NC, Vetter EA, et al. Desulfovibrio legallii prosthetic shoulder joint infection and review of antimicrobial susceptibility and clinical characteristics of Desulfovibrio infections. J Clin Microbiol. 2014;52:3105–10.CrossRef Vasoo S, Mason EL, Gustafson DR, Cunningham SA, Cole NC, Vetter EA, et al. Desulfovibrio legallii prosthetic shoulder joint infection and review of antimicrobial susceptibility and clinical characteristics of Desulfovibrio infections. J Clin Microbiol. 2014;52:3105–10.CrossRef
21.
Zurück zum Zitat Koyano S, Tatsuno K, Okazaki M, Ohkusu K, Sasaki T, Saito R, et al. A case of liver abscess with Desulfovibrio desulfuricans bacteremia. Case Rep Infect Dis. 2015;2015:354168.PubMedPubMedCentral Koyano S, Tatsuno K, Okazaki M, Ohkusu K, Sasaki T, Saito R, et al. A case of liver abscess with Desulfovibrio desulfuricans bacteremia. Case Rep Infect Dis. 2015;2015:354168.PubMedPubMedCentral
22.
Zurück zum Zitat Yamazaki T, Joshita S, Kasuga E, Horiuchi K, Sugiura A, Fujimori N, et al. A case of liver abscess co-infected with Desulfovibrio desulfuricans and Escherichia coli and review of the literature. J Infect Chemother. 2017;24:393–7.CrossRef Yamazaki T, Joshita S, Kasuga E, Horiuchi K, Sugiura A, Fujimori N, et al. A case of liver abscess co-infected with Desulfovibrio desulfuricans and Escherichia coli and review of the literature. J Infect Chemother. 2017;24:393–7.CrossRef
23.
Zurück zum Zitat Nasreddine R, Argudin MA, Herpol M, Deyi VYM, Dauby N. First case of Desulfovibrio desulfuricans bacteraemia successfully identified using MALDI-TOF MS. New Microbes New Infect. 2019;32:100614.CrossRef Nasreddine R, Argudin MA, Herpol M, Deyi VYM, Dauby N. First case of Desulfovibrio desulfuricans bacteraemia successfully identified using MALDI-TOF MS. New Microbes New Infect. 2019;32:100614.CrossRef
24.
Zurück zum Zitat Marquis TJ, Williams VJ, Banach DB. Septic arthritis caused by Desulfovibrio desulfuricans: a case report and review of the literature. Anaerobe. 2021;70:102407.CrossRef Marquis TJ, Williams VJ, Banach DB. Septic arthritis caused by Desulfovibrio desulfuricans: a case report and review of the literature. Anaerobe. 2021;70:102407.CrossRef
25.
Zurück zum Zitat Chesdachai S, Eberly AR, Razonable RR. A tale of two unusual anaerobic bacterial infections in an immunocompetent man: a case report and literature review. Anaerobe. 2021;71:102416.CrossRef Chesdachai S, Eberly AR, Razonable RR. A tale of two unusual anaerobic bacterial infections in an immunocompetent man: a case report and literature review. Anaerobe. 2021;71:102416.CrossRef
26.
Zurück zum Zitat Johnson CC, Finegold SM. Uncommonly encountered, motile, anaerobic gram-negative bacilli associated with infection. Clin Infect Dis. 1987;9:1150–62.CrossRef Johnson CC, Finegold SM. Uncommonly encountered, motile, anaerobic gram-negative bacilli associated with infection. Clin Infect Dis. 1987;9:1150–62.CrossRef
27.
Zurück zum Zitat Akshatha R, Biswas R, Sasidharan GM, Das S. Uncommon isolation of Desulfovibrio vulgaris from a depressed fracture wound on the forehead. Anaerobe. 2020;65:102264.CrossRef Akshatha R, Biswas R, Sasidharan GM, Das S. Uncommon isolation of Desulfovibrio vulgaris from a depressed fracture wound on the forehead. Anaerobe. 2020;65:102264.CrossRef
28.
Zurück zum Zitat Baron EJ, Bennion R, Thompson J, Strong C, Summanen P, McTeague M, et al. A microbiological comparison between acute and complicated appendicitis. Clin Infect Dis. 1992;14:227–31.CrossRef Baron EJ, Bennion R, Thompson J, Strong C, Summanen P, McTeague M, et al. A microbiological comparison between acute and complicated appendicitis. Clin Infect Dis. 1992;14:227–31.CrossRef
29.
Zurück zum Zitat Langendijk PS, Kulik EM, Sandmeier H, Meyer J. Hoeven JS van der. Isolation of Desulfomicrobium orale sp. nov. and Desulfovibrio strain NY682, oral sulfate-reducing bacteria involved in human periodontal disease. Int J Syst Evol Microbiol. 2001;51:1035–44.CrossRef Langendijk PS, Kulik EM, Sandmeier H, Meyer J. Hoeven JS van der. Isolation of Desulfomicrobium orale sp. nov. and Desulfovibrio strain NY682, oral sulfate-reducing bacteria involved in human periodontal disease. Int J Syst Evol Microbiol. 2001;51:1035–44.CrossRef
30.
Zurück zum Zitat Loubinoux J, Bisson-Boutelliez C, Miller N, Faou AEL. Isolation of the provisionally named Desulfovibrio fairfieldensis from human periodontal pockets. Oral Microbiol Immunol. 2002;17:321–3.CrossRef Loubinoux J, Bisson-Boutelliez C, Miller N, Faou AEL. Isolation of the provisionally named Desulfovibrio fairfieldensis from human periodontal pockets. Oral Microbiol Immunol. 2002;17:321–3.CrossRef
31.
Zurück zum Zitat Ishigami J, Matsushita K. Clinical epidemiology of infectious disease among patients with chronic kidney disease. Clin Exp Nephrol. 2019;23:437–47.CrossRef Ishigami J, Matsushita K. Clinical epidemiology of infectious disease among patients with chronic kidney disease. Clin Exp Nephrol. 2019;23:437–47.CrossRef
32.
Zurück zum Zitat Lantinga MA, Casteleijn NF, Geudens A, de Sévaux RGL, van Assen S, Leliveld AM, et al. Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review. Nephrol Dial Transplant. 2017;32:144–50.PubMed Lantinga MA, Casteleijn NF, Geudens A, de Sévaux RGL, van Assen S, Leliveld AM, et al. Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review. Nephrol Dial Transplant. 2017;32:144–50.PubMed
33.
Zurück zum Zitat Sallée M, Rafat C, Zahar J-R, Paulmier B, Grünfeld J-P, Knebelmann B, et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4:1183–9.CrossRef Sallée M, Rafat C, Zahar J-R, Paulmier B, Grünfeld J-P, Knebelmann B, et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4:1183–9.CrossRef
34.
Zurück zum Zitat Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. Lancet Infect Dis. 2004;4:337–48.CrossRef Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. Lancet Infect Dis. 2004;4:337–48.CrossRef
35.
Zurück zum Zitat Jouret F, Lhommel R, Devuyst O, Annet L, Pirson Y, Hassoun Z, et al. Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities. Nephrol Dial Transplant. 2012;27:3746–51.CrossRef Jouret F, Lhommel R, Devuyst O, Annet L, Pirson Y, Hassoun Z, et al. Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities. Nephrol Dial Transplant. 2012;27:3746–51.CrossRef
36.
Zurück zum Zitat Piccoli GB, Arena V, Consiglio V, Deagostini MC, Pelosi E, Douroukas A, et al. Positron emission tomography in the diagnostic pathway for intracystic infection in adpkd and “cystic” kidneys. A case series. BMC Nephrol. 2011;12:48–8.CrossRef Piccoli GB, Arena V, Consiglio V, Deagostini MC, Pelosi E, Douroukas A, et al. Positron emission tomography in the diagnostic pathway for intracystic infection in adpkd and “cystic” kidneys. A case series. BMC Nephrol. 2011;12:48–8.CrossRef
37.
Zurück zum Zitat Chapman AB, Devuyst O, Eckardt K-U, Gansevoort RT, Harris T, Horie S, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2015;88:17–27.CrossRef Chapman AB, Devuyst O, Eckardt K-U, Gansevoort RT, Harris T, Horie S, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2015;88:17–27.CrossRef
38.
Zurück zum Zitat Bennett WM, Elzinga L, Pulliam JP, Rashad AL, Barry JM. Cyst fluid antibiotic concentrations in autosomal-dominant polycystic kidney disease. Am J Kidney Dis. 1985;6:400–4.CrossRef Bennett WM, Elzinga L, Pulliam JP, Rashad AL, Barry JM. Cyst fluid antibiotic concentrations in autosomal-dominant polycystic kidney disease. Am J Kidney Dis. 1985;6:400–4.CrossRef
Metadaten
Titel
First case of a renal cyst infection caused by Desulfovibrio: a case report and literature review
verfasst von
Yoshiki Okamoto
Yoei Miyabe
Momoko Seki
Yusuke Ushio
Keisuke Sato
Eri Kasama
Kenichi Akiyama
Kazunori Karasawa
Keiko Uchida
Ken Kikuchi
Kosaku Nitta
Takahito Moriyama
Junichi Hoshino
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
BMC Nephrology / Ausgabe 1/2022
Elektronische ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02803-w

Weitere Artikel der Ausgabe 1/2022

BMC Nephrology 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.